

**Important initiatives/decisions taken during last three years & ten months (May 2014- Mar 2018) of the Government**

**1. National Pharmaceutical Pricing Authority (NPPA)**

**(I) Price Fixation:**

Department of Pharmaceuticals vide notification no. 701 (E) dated 10.03.2016 amended Schedule-I of DPCO, 2013 substituting NLEM, 2011 with NLEM, 2015. NPPA has fixed the ceiling prices of 851 scheduled medicines under NLEM -2015 incorporated under Schedule I of DPCO, 2013.

The number of fixation of ceiling price/Retail Price is as follows:

	<b>No of formulations</b>
Ceiling prices	851
Retail Prices upto 31.03.2018	665 (out of which 613 was during 2014-2018)

The details of reduction in prices of scheduled formulations effected under DPCO, 2013 as compared to the highest price prevailed prior to the announcement of DPCO, 2013 are as follows:

<b>% reduction with respect to Maximum Price</b>	<b>No. of medicines NLEM 2011 (Original Schedule-I)</b>	<b>No. of medicines NLEM 2015 (Revised Schedule-I) (During 2016-2018)</b>
0<= 5%	80	234
5<=10%	50	134
10<=15%	57	98
15<=20%	43	98
20<=25%	65	93
25<=30%	49	65
30<=35%	26	46
35<=40%	34	24
Above 40%	126	59
<b>TOTAL</b>	<b>530</b>	<b>851</b>

The therapeutic group wise details of price fixation done are as under:

<b>Therapeutic group</b>	<b>No. of medicines (during 2016-2018)</b>
Anticancer	72
Anti-TB	28
Anti-HIV	41
Anti-diabetic	12
Cardiovascular	70
Others	628

Total	851
-------	-----

### Retail Prices

NPPA also fixed and notified retail prices of 665 formulations upto 31.03.2018 (613 during April-2014 to Mar-2018) for company specific new drugs as per para 2(u) of DPCO 2013.

### **Medical Devices:**

Government notified inclusion of coronary stents in the National List of Essential Medicines 2015 (NLEM 2015) vide notification dated 19th July 2016 and subsequently in the First Schedule of Drugs (Prices Control) Order 2013 (DPCO, 2013) vide notification dated 21<sup>st</sup> December 2016. In accordance with para 17(1) of DPCO, 2013, National Pharmaceutical Pricing Authority (NPPA) is mandated to fix the ceiling prices of Coronary stents.

NPPA has fixed the ceiling price of coronary stents vide OM dated 13.02.2017 as specified below:

Stents	Average MRP Earlier )Rupees( ( before Price Cap)	Average Price Reduction	New Ceiling Price and MRP* )Rupees( (after Price Cap)
Drug Eluting Stents (DES) including metallic DES and Bioresorbable Vascular Scaffold (BVS)/ Biodegradable Stents	121,400	76%	29,600 ( Revised to Rs. 28,849 Wef 1.4.18)
Bare Metal Stents	45,100	84%	7,260 ( Revised to Rs. 7,923 wef 1.4.2018)

Vide Gazette Order SO 2668(E), dated 16.08.2017, National Pharmaceutical Pricing Authority (NPPA) has notified the ceiling prices of knee Implant system. The notified ceiling prices are effective from August 16, 2017, the date of its publication in Government Gazette. The NPPA, while fixing the ceiling prices, has kept interest of all the stakeholders in mind and prices have been fixed accordingly, which are as follows:

Type of Knee Implant	Average MRP Earlier (Rupees)	Average Price Reduction	New Ceiling Price and MRP* (Rupees)
Cobalt Chromium (most	1,58,324	65%	54,720

widely used)			
Special Metal like Titanium & Oxidized Zirconium	2,49,251	69%	76,600
High Flexibility Implant	1,81,728	69%	56,490
Revision Implants	2,76,869	59%	1,13,950

*\*Companies will print the MRP by adding GST on these ceiling prices*

### **Saving to Consumers**

The Government has helped the consumers since May, 2014 by implementing the provisions of DPCO, 2013 made the following savings:-

Particulars	Saving to Consumers in Rs. Crores
<b>NLEM-2011</b>	
Under NLEM-2011 upto May 2014	2221
Under NLEM-2011 from May-2014 to Feb-2016	201
<b>NLEM-2015</b>	
Under NLEM-2015 from Mar-2016 till 31.03.2018	2643
Coronary Stents in Feb-2017/2018	4547
Under Para 19 (extraordinary circumstances) in July, 2014	350
Knee Implants in Aug-2017	1500
<b>TOTAL</b>	<b>11462</b>

TOTAL Saving under DPCO 2013 (15.5.2013 to 30.4.2014)

Rs 2,221 Crores

TOTAL Saving under DPCO 2013 (1.5.2014 to 30.4.2018)

Rs 9,241 Crores

### **Details of the price fixation of schedule formulation by NPPA w.e.f. 01.04.2010 to 31.03.2018**

S.No.	Period	Ceiling Price	Retail Price	Saving to Consumer (Rs. In Crores)
<b>I. for the period 1.4.2010 to 31.03.2014 (four years)</b>				
	<b>Under DPCO 1995</b>			
1	01.04.2010 to 31.03.2011	551	162	Note 1
2	01.04.2011 to 31.03.2012	480	127	
3	01.04.2012 to 31.03.2013	411	99	
	<b>Subtotal (A)</b>	<b>1442</b>	<b>388</b>	
	<b>Under DPCO 2013</b>			
4	01.04.2013 to 31.03.2014 (B)	404	52	2221
	<b>TOTAL C =(A+B)</b>	<b>1846</b>	<b>440</b>	<b>2221</b>

<b>II. for the period 1.4.2014 to 31.03.2018 ( four years)</b>				
	<b>Under DPCO 2013</b>			
5	01.04.2014 to 31.03.2015	62	108	9241
6	01.04.2015 to 31.03.2016	104	124	
7	01.04.2016 to 31.03.2017	334	157	
8	01.04.2017 to 31.03.2018	122	224	
	<b>Total (D)</b>	<b>622</b>	<b>613</b>	<b>9241</b>
<b>Note 1: Saving has not been computed under DPCO 1995</b>				

S.No.	Period	Date	Ceiling Price	Retail Price	Saving to Consumer (Rs. In Crores)	II. for the period 1.4.2014 to 31.03.2018 ( four years)				
I. for the period 1.4.2010 to 31.03.2014 (four years)							Under DPCO 2013			
	Under DPCO 1995					5	01.04.2014 to 31.03.2015	62	108	9241
1	01.04.2010 to 31.03.2011		551	162	Note 1	6	01.04.2015 to 31.03.2016	104	124	
2	01.04.2011 to 31.03.2012		480	127		7	01.04.2016 to 31.03.2017	334	157	
3	01.04.2012 to 31.03.2013		411	99		8	01.04.2017 to 31.03.2018	122	224	
	Subtotal (A)		1442	388			Total (D)	622	613	9241
	Under DPCO 2013									
4	01.04.2013 to 31.03.2014 (B)		404	52	2221					
	TOTAL C =(A+B)		1846	440	2221					
Note 1: Saving has not been computed under DPCO 1995										

**(II) Status of Overcharging & Recovery****(Rs. In Crores)**

Particulars	DPCO,1995	DPCO,2013	Total (in Rs.)
Total Recovery since inception of NPPA ( i.e from 1997 to March 2018)	281.46	546.48	827.94
Recovery during April 2014 to March 2018	281.44	271.55	552.99

**(III) New Initiatives:****(i) Pharma Jan Samadhan (PJS)**

Pharma Jan Samadhan (PJS) was launched on 12th March, 2015. PJS is a web enabled system developed by the NPPA with the assistance of National Informatics Centre (NIC). PJS serves as a robust e-governance tool for protection of consumer interest through effective implementation of the Drugs (Price Control) Order 2013. The primary objective of PJS is to put in place a speedy and effective complaint redressal system with respect to availability of medicines, overpricing of medicines, sale of 'new drugs' without prior price approval (WPA) and refusal of supply or sale of medicines.

**(ii) Pharma Data Bank (PDB) - IPDMS**

Pharma Data Bank - an Integrated Pharmaceutical Database Management System (IPDMS) was launched by the Hon'ble Minister of Chemicals and Fertilizers on 25<sup>th</sup> June, 2015. PDB has been developed by NPPA in collaboration with the National Informatics Centre (NIC). This comprehensive online system provides a platform to the Pharmaceutical Manufacturer/ Marketing/ Importer/ Distributor Companies to file mandatory returns prescribed in Form II, Form III and Form V of Drugs (Prices Control) Order, 2013 (DPCO, 2013). Companies were given a deadline of 10.05.2017 for filing all mandatory forms through Pharma Data Bank - IPDMS.

**(iii) 'Pharma Sahi Daam'.**

NPPA has developed in collaboration with NIC, Android and iOS versions of mobile-app 'Pharma Sahi Daam' which provides information to consumers on prices of Scheduled medicines which are under price regulation as well as Non Scheduled medicines. With this mobile app, a consumer can check the prices of scheduled and non-scheduled medicines instantly at the time of purchase of the medicine. More than one lakh users have downloaded this app.

(iv) NPPA has also launched its twitter handle @NPPA\_india in order to disseminate information regarding policies and achievements of the Government and also for getting feedback from public and other stakeholders. There are more than 4800 followers of this handle.

## **2. National Institute of Pharmaceutical Education and Research (NIPER):**

NIPER Mohali bagged rank Number 2 and NIPER Hyderabad as Number 5 in National Institute Ranking Framework Survey 2017. **NIPER Mohali has bagged rank Number 1, NIPER Hyderabad as Number 6 and NIPER Ahmedabad as Number 14 in NIRF Survey 2018.**

### **a. Opening of New NIPERs:**

During 2015–16, Government announced opening of three NIPERs at Maharashtra, Rajasthan and Chhattisgarh.

(i) State Government of Rajasthan has allotted 100 acres of land in Village Prithvipura Tehsil Asnawar, Jhalawar for NIPER Rajasthan. A lease agreement has been completed.

(ii) Government of Maharashtra has allocated 61 acres of land in Mauza Kaldongari, Tahsil Nagpur (Rural), Nagpur District for establishment of NIPER. The land has been approved by the Department. The State Government has sent a Draft Lease Agreement for transferring to said land to the Department.

(iii) State Govt. of Chhattisgarh has intimated that only 35 acres of land is available at the already selected site by the Department. They have suggested 2 different sites of 63 acres and 116.94 acres for NIPER. They have requested the Department to finalize the land for NIPER.

### **b. Foundation for old NIPERs building:**

(i) Foundation for NIPER Guwahati was laid on 31.5.2015. Construction was started in June 2015; 42% work has been completed.

(ii) Foundation for NIPER Ahmedabad was laid in December 2015. NIPER, Ahmedabad is functioning through a temporary constructed building on land allocated by the Government of Gujarat in Gandhinagar.

(iii) 50.00 acres land allotted for NIPER Hyderabad at District Medak. Possession of land has been taken. PMC for NIPER, Hyderabad has been approved.

(iv) Govt. of West Bengal has recently allotted 10 acres of land at Nadia District for NIPER Kolkata.

(iv) Govt. of Uttar Pradesh allotted 58.57 acres land at Tehsil Maharajganj, Raebareli for NIPER Raebareli. Possession has been taken.

(v) Govt. of Bihar has proposed 12.5 acres of land for NIPER Hajipur. It has been decided to accept the same

### **c. Fund released during last four years:**

<b>Sl. No.</b>	<b>Year</b>	<b>Amount (Rs. in crore)</b>
1.	2014-15	56.42
2.	2015-16	122.75
3.	2016-17	127.48
4.	2017-18	178.27

**d. Total No. of students of NIPERs passed out during the last four years**

Year	Number
2014	543
2015	560
2016	590
2017	637

**e. Revenue Generation in NIPERs**

Year	Amount (Rs. in Lakhs)
2014-15	491.73
2015-16	568.505
2016-17	662.74

**3. Major Policy Initiatives:**

**a. Uniform Code for Pharmaceuticals Marketing Practices**

To curb unethical practices in the healthcare sector a Uniform Code for Pharmaceuticals Marketing Practices (UCPMP) has been prepared and voluntarily adopted and complied with by the Pharma Industry with effect from 01.01.2015.

After reviewing the implementation of UCPMP the Department is in the process of making a statutory order for controlling the unethical practices being adopted by some Pharmaceutical companies in consultation with the Ministry of Law.

**b. Amendments to DPCO, 2013:**

The Committee constituted by the Department for ensuring enhanced accessibility of drugs to the poor has since submitted its recommendations. These recommendations have been examined and the issue of amending the provisions of Drugs (Prices Control) Order, 2013 (DPCO-2013), is now under active consideration.

**c. Scheme for Development of Pharmaceutical Industry:**

Department has prepared an umbrella scheme namely 'Scheme for Development of Pharmaceutical Industry' which has been approved by the Standing Finance Committee (SFC) in its meeting on 7.2.2018. The said scheme is a Central Sector Scheme(CSS) with a total financial outlay of Rs. 480 crores and comprises of the following sub schemes:-

- (a) Assistance to Bulk Drug Industry for Common Facility Centre;
- (b) Assistance to Medical Device Industry for Common Facility Centre;
- (c) Pharmaceuticals Technology Upgradation Assistance Scheme (PTUAS);
- (d) Cluster Development Programme for Pharma Sector(CDP-PS); and
- (e) Pharmaceutical Promotion and Development Scheme (PPDS).

Among the sub-schemes, CDP-PS and PPDS are existing schemes of the department. It is expected that the implementation of the scheme would facilitate the growth of domestic pharmaceutical industry to play a lead role in the global market and

ensure the availability of good quality pharmaceuticals of mass consumption thereby assuring drug security in the country.

**d. Promotion of Generics:**

The Department besides operating a scheme Pradhan Mantri Bhartiya Janaushadhi Pariyojna(PMBJP) which sells low cost generics in the country has also taken up with M/o Health & Family Welfare for taking up promotion of generics in a big way.

**4. 'Pradhan Mantri Bhartiya Janaushadhi Pariyojana' (PMBJP)**

**About Scheme:** In order to make available quality generic medicines at affordable prices to all through specific outlets, 'Pradhan Mantri Bhartiya Janaushadhi Pariyojana' (PMBJP) was launched by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India in November, 2008 across the country. The specific outlets are called 'Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) Kendras'. The scheme is being implemented through an agency namely Bureau of Pharma PSUs of India (BPPI) (the implementing agency of PMBJP) which is working under the administrative control of Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India.

**Progress report:**

PARAMETER	UPA	NDA
Name of Scheme	Jan Aushadhi Scheme (JAS)	Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)
<b>Number of PMBJP Kendras</b>	As on 31.03.2009 – 4 As on 31.03.2010 – 23 As on 31.03.2011 – 30 As on 31.03.2012 – 47 As on 31.03.2013 – 72 As on 31.03.2014 – 78 Upto May, 2014 – 99	Upto May, 2014 – 99 As on 31.03.2015 – 99 As on 31.03.2016 – 269 As on 31.03.2017 – 1080 As on 08.12.2017 – 3000 As on 31.03.2018 – 3322 As on 21.5.2018 - 3578
<b>Sales Position of the Scheme</b>	2013-14 - NIL	2014-15 – Rs. 5.61 Crores 2015-16 – Rs. 9.35 Crores 2016-17 – Rs. 26.03 Crores 2017-18 – Rs. 108.34 Crores 2018-19 – Rs. 17.10 Crores (As on 21.05.2018)
<b>Eligibility</b>	PMBJP Kendras	(i) Besides Government Hospital/ Medical



<b>conditions of Operating Agencies</b>	opened in Government Hospital/ Medical College premises only	<p>College premises, the scheme guidelines have been amended to open PMBJP Kendras by State Government/ State Government nominated agencies in any Government building premises owned by Government bodies like Railways/ State Transport Department/ Urban local bodies/ Panchayati Raj Institutions/ Post Offices/ Defence/ PSUs etc.</p> <p>(ii) Any NGO/ Charitable Society/ Institution/ Self-Help Group/ Unemployed Pharmacist/ Doctor/ Registered Medical Practitioners/ Individual Entrepreneur can open PMBJP Kendra.</p> <p>(iii) PMBJP Kendra owners allowed to sell non-competitive products like Nutraceuticals, Cold drinks, etc.</p>
<b>Financial Assistance to Government PMBJP Kendras</b>	Rs. 1.5 Lakhs	<p>Rs. 2.50 Lakhs</p> <p>For opening PMBJP Kendras in Government Hospital / Medical College / any Government owned building premises, one-time financial assistance upto Rs. 2.50 lakh is provided.</p>
<b>Financial Assistance to Private PMBJP Kendras</b>	Rs. 1.5 Lakhs	<p>Rs. 2.50 Lakhs</p> <p>(i) The applicants that are linked with BPPI Headquarters through internet (using BPPI provided software) will get incentive upto Rs. 2.5 lakhs @ 15% of monthly sales subject to a ceiling of Rs. 10,000/- Per Month and in case of the applicants belonging to weaker sections like SC/ ST/ differently abled, medicines worth Rs. 50,000/- are also provided in advance.</p> <p>(iii) In north-eastern states, naxal-affected areas and tribal areas, the rate of incentive will be 15% and subject to a monthly ceiling of Rs. 15,000/- upto a total limit of Rs. 2.5 lakhs.</p>
<b>Coverage of Scheme Presence</b>	16 States/UTs	33 States /UTs
<b>Product basket</b>	361 medicines	700+ medicines and 154 surgicals and consumables
<b>Medicines available in Central Ware House (CWH)</b>	90-100	668 medicines and 86 surgicals & consumables

<b>of BPPI</b>		
<b>Sanitary Napkins</b>	--	Recently, Government has announced the launching of Oxo-biodegradable Sanitary Napkin under PMBJP which will be made available at all PMBJP Kendras across the country soon at the price of Rs.10/- for the pack of 4 sanitary pads which comes to Rs. 2.50 per pad. It will ensure affordability, hygiene as well as ease of use and disposal.
<b>Coverage of Therapeutic Groups</b>	Product basket was incomplete.	Product basket now covers all major therapeutic categories such as Anti-infective, Anti-diabetic, Cardiovascular, Anti-cancer, Gastro-intestinal medicines, etc.
<b>Procurement of medicines</b>	Central Pharma PSUs for 138 medicines based on the Purchase Preference Policy (PPP) model	Central Pharma PSUs + 150 private manufacturers [World Health Organization – Good Manufacturing Practice (WHO-GMP)] & surgical suppliers
<b>Quality Testing</b>	At source (CPSUs level)	At source level as well as at National Accreditation Board for Testing and Calibration Laboratories (NABL) empanelled with BPPI
<b>Supply Chain Management</b>	Non-existent	<ul style="list-style-type: none"> <li>Professional agency to manage entire supply chain starting from Central Warehouse (CWH) of BPPI to Carrying &amp; Forwarding (C&amp;F) Agents and Distributors. 8 C&amp;F Agents and 53 Distributors are part of this supply chain.</li> <li>Recently, an end-to-end supply chain system has also been introduced for making available full range of medicines from Central Ware House (CWH) to PMBJP Kendras directly to save time and cost.</li> </ul>
<b>Pricing</b>	MRP calculated on PPP rates (10% to 25 % less compare to branded products of open market)	Prices are 50-90% less than that of branded prices
<b>Savings</b>	10% to 25% as compared with branded rates	36 Products - 90-99% savings 130 Products - 80-90% savings 73 Products - 70-80% savings 80 Products - 60-70% savings 383 Products - 50-60% savings
<b>Trade Margin for PMBJP Kendras retailers</b>	16%	20%

<b>Trade Margin for Distributors</b>	8%	10%
<b>Media</b>	Used to give advertisement only in news papers, as and when required	Initiated various media and publicity campaigns around each Jan Aushadhi Kendra's to educate the common public about the difference in the prices of medicines through print media, television, FM radio, Outdoor publicity, Social Media.

### **Comparative Price Statement of PMBJP Medicines & Branded Medicines**

<b>PRICE COMPARISON CHART</b>					
<b>S. No.</b>	<b>Name of Medicines</b>	<b>Pack Size</b>	<b>Average Price of leading brands (In Rs.)</b>	<b>PMBJP MRP (In Rs.)</b>	<b>Price Differences</b>
<b>Cardiovascular Agents</b>					
1	Amlodipine 5 mg and Atenolol 50 mg film coated Tablets	10's	36.86	3.54	10 times
2	Ramipril 5 mg Tablets	10's	72.8	9.68	8 times
3	Losartan 50 mg and Hydrochlorthiazide 12.5mg Tablets	10's	68.23	9.05	8 times
4	Rosuvastatin Tablets IP 20 mg	10's	211	27.34	8 times
5	Atorvastatin 10 mg Tablets	10's	50.9	5.11	10 times
<b>Anti-diabetic Agents</b>					
1	Glimepiride 2 mg Tablets	10's	52.9	5.05	10 times
2	Glimepiride 2 mg + Metformin Hydrochloride 500 mg SR Tablets	10's	60.44	17.78	4 times
3	Metformin HCL 500 mg Tablets	10's	13.9	5.15	3 times
<b>Anti-Cancer</b>					
1	Bicalutamide Tabes IP 50 mg	10's	636	137.5	5 times
2	Paclitaxel Inj 100 mg	Vial	3458	540	6 times
3	Imatinib Mesylate Tablets IP 400 mg	10's	2133	477	4 times
<b>Gastro-intestinal Tract Agents</b>					
1	Rabeprazole 20 mg Tablets	10's	54	7.16	8 times
2	Pantoprazole 40 mg Tablets	10's	63	7.2	9 times
3	Domperidone 30 mg+ Pantoprazole 40 mg Capsules	10's	86	18.48	5 times
<b>Antibiotics</b>					
1	Amoxycillin 500mg + Clavulanic acid 125 mg Tablets	6's	96.84	52.24	2 times
2	Cefixime 100 mg Tablets	10's	82.6	25.65	3 times
3	Ofloxacin 200mg Tablets	10's	52.6	14.8	4 times
4	Azithromycin 500 mg Tablets	10's	178.3	86.6	2 times
<b>Analgesic/Anti-inflammatory/Anti-pyretic Drugs</b>					

1	Tramadol 50mg Tabets	10's	60	4.38	14 times
2	Nimesulide 100 mg Tablets	10's	39	2.52	15 times
3	Diclofenac Sodium+Serratiopeptidase(50 mg+10 mg) tablets	10's	103.2	7.02	15 times

## 5. **'Pharmaceutical Promotion and Development Scheme' (PPDS)**

**About Scheme:** The Objective of 'Pharmaceuticals Promotion Development Scheme' (PPDS) is promotion, development and export promotion in Pharmaceutical sector by extending financial support for conducting seminars, conferences, exhibitions, mounting delegations to and from India for promotion of exports as well as investments, conducting studies/consultancies, for facilitating growth, exports as well as critical issues affecting Pharma sector. During 2014-15 to 2017-18, financial assistances were given to various organizations for conducting following Conferences/Seminars/Workshops for promotion of indian pharma industries.

1. Meeting of India-US High Technology Cooperation Group(HTCG) and G2G Working Group on Biotechnology and Life Science under India-US High Technology Cooperation Group(HTCG) was held on 20<sup>th</sup> and 21<sup>st</sup> November, 2014 at New Delhi.
2. An Indian Pharma delegation, under the chairmanship of Shri Sudhansh Pant, Joint Secretary(Pharma) visited Suriname from 7-10 April, 2015 for assisting in upgrading the pharmaceuticals production facility and pharmaceuticals waste disposal facilities in Suriname.
3. Video Conference of India-EU Joint Working Group on Pharmaceuticals, Biotechnology and Medical Devices on 30<sup>th</sup> April, 2015 – 1<sup>st</sup> May, 2015, a Video Conference was held with European Union on 26<sup>th</sup> November, 2015.
4. An Indian Pharma delegation, under the chairmanship of Dr. M. Ariz Ahammad, Joint Secretary, visited USA to participate in US-India BioPharma and Healthcare Summit at Boston(USA) on 11<sup>th</sup> June, 2015; Drugs Information Association (DIA) Annual Meeting at Washington DC (USA) on 14-15 & 17<sup>th</sup> June, 2015; and Bio2015 Convention at Philadelphia(USA) on 16-17 June, 2015
5. 2<sup>nd</sup> JWG Meeting between India and Fiji on Cooperation in the field of health and medicine in Suva, Fiji under the chairmanship of Joint Secretary, Ministry of Health & Family Welfare.
6. 1<sup>st</sup> India Pharma Awards on 7.1.2016 at Bengaluru.
7. 1<sup>st</sup> India Pharma 2016 and India Medical Expo 2016 at Bengaluru from 7-9 January, 2016.
8. 2<sup>nd</sup> Meeting of India-Ukraine Joint Working Group on Pharmaceuticals and Healthcare held on 21-22 January 2016 in Ukraine.
9. A delegation led by Dr. M.A. Ahammed, Joint Secretary, Department of Pharmaceuticals participated in 10<sup>th</sup> Annual BioPharma & Health Summit 2016 held on 02.06.2016 at Boston (USA)
10. 7<sup>th</sup> Meeting of EU-India Joint Working Group on Pharmaceuticals, Biotechnology and Medical Devices was held on 5-6 July 2016 at Brussels under the Co-chairmanship of Shri Sudhansh Pant, Joint Secretary, Department of Pharmaceuticals.
11. 1st Meeting of India-Belarus Joint Working Group on Pharmaceuticals held on 20 January, 2017 at New Delhi

12. 6<sup>th</sup> Meeting of India-Tunisia Joint Working Group on Drugs & Pharmaceuticals on 11-13 January, 2017 at Tunis under the Co-chairmanship of Shri Sudhansh Pant, Joint Secretary, Department of Pharmaceuticals
13. 2<sup>nd</sup> India Pharma 2017 and India Medical Device 2017 on 11-13 February 2017 at Bengaluru.
14. 2<sup>nd</sup> India Pharma 2017 and Medical Device Awards on 11.2.2017 at Bengaluru.
15. 8<sup>th</sup> Meeting of India-EU Joint Working Group on Pharmaceuticals, Biotechnology and Medical Devices was held on 13-14 July, 2017 at New Delhi
16. Meeting of Mr. Dusmuratov Mirzanzolim Mirzabekovich, Uzbek Minister of Pharmaceuticals visited India from 21-23 August, 2017 with Shri Ananth Kumar, Hon'ble Minister (Chemicals & Fertilizers) on 22.08.2017 to discuss mutual co-operation in the field of pharmaceuticals
17. Video Conference Meeting of India-EU Joint Working Group on Pharmaceuticals, Biotechnology and Medical Devices held on 19.01.2018
18. 3<sup>rd</sup> India Pharma and Medical Device Awards on 15.2.2018 at Bengaluru.
19. 3<sup>rd</sup> India Pharma 2018 and India Medical Device 2018 on 15-17 February 2018
20. An Indian Pharma Delegation, led by Shri Mansukh L. Mandaviya, Hon'ble Minister of State (C&F) visited Uzbekistan from 21.02.2018 to 23.02.2018 for bilateral discussions

**India Pharma 2018 and India Medical Device 2018:** During the Conference of 3<sup>rd</sup> edition of International Exhibitions & Conferences on Pharmaceuticals and Medical Devices sectors 2018 (India Pharma 2018 and India Medical Device 2018) held at Bangalore from 15-17 February 2018, nine (9) countries including India namely United States of America (USA), European Union, Russia, Singapore, Mexico, Ghana and large number of delegates of World Health Organization (WHO) participated as a International drug regulator. Apart from this, 39 Chief Executive Officers (CEO)s from different pharmaceutical companies also participated the Conference. A Conference was also held by National Association of Software and Services Companies (**NASSCOM**) for Digital Transformation through Innovation in Pharmaceutical, Medical Devices and Healthcare Industries.

